Zhang Y, Zhao X, Dong X, Zhang Y, Zou H, Jin Y, et al
As our knowledge of GLP-1 biology advances and novel therapeutic innovations arise, these agents are expected to assume a progressively pivotal role in the management of metabolic disorders and their related complications, ultimately enhancing patient outcomes across various disease states
2017;26(2):343352 e342
A 2022 analysis of the SUSTAIN and STEP trial data published in Obesity Reviews found a clear and consistent relationship between dose escalation speed and gastrointestinal side effect severity
The bidirectional effects of NMDA receptor antagonism on feeding could potentially diminish the weight-lowering efficacy of systemic exposure to NMDA receptor antagonists
Graham Lipkin, a Consultant Nephrologist at Queen Elizabeth Hospital Birmingham, highlights this risk: "Some of the side effects of GLP-1 medicines include dehydration, which can result in acute kidney injury (AKI)